Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia

Open access journal of the Ferrata-Storti Foundation, a non-profit organization

Letters to the Editor

Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell / myeloid mixed phenotype acute leukemia

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston – TX

Haematologica Early view Jun 26, 2025 https://doi.org/10.3324/haematol.2025.287932

Not available.

Early view : Letters to the Editor

DOI

Published

2025-06-26

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

Online Views

147

PDF Downloads

No Data